Related posts
26 Stock Top Picks and 4 Top ETFs (Oct 19-25)This summary was created by AI, based on 1 opinions in the last 12 months.
Innodata Isogen Inc. (INOD-Q) has attracted mixed opinions from financial experts, with some suggesting that the stock has become significantly expensive in recent times. Investors are advised to consider taking profits, reflecting concerns about the company's current valuation compared to its historical performance. The prevailing sentiment indicates that while the company has had its successes, the recent surge in price might lead to diminished returns for shareholders if they do not act prudently. As such, a cautious approach may be warranted for those considering entering or maintaining positions in this stock. Overall, that leads to a more guarded outlook on its future price movements.
(A Top Pick Dec 22/16. Down 50%.) This deals with digitalization, things like e-books. On the conference calls, they are always super optimistic. In the last 2 conference calls, they weren’t. Sales have flatlined and they’ve been losing money. Expects that over the next 5 weeks there will be tax loss selling on this. He is happy to hold it, but it probably won’t pay off for quite a while.
(A Top Pick Sept 22/16. Down 46%.) Has been horrible, but this has a tendency to pop about every 3 years. They do digitalization for e-books, etc. When you listen to conference calls, it always sounds like they are going to be doing really well. Unfortunately, on the last conference call, they seemed to lose their confidence to some degree. There is a reasonable chance it could come down further in the tax loss season. Remains on his watch list, and he continues to buy it. Wouldn't be buying this today or tomorrow, but would wait to see if there is more tax loss selling.
(A Top Pick June 28/16. Down 36%.) This was a bad pick all along. About every 3 years it has a spike, and the last one was around 2012 so it is now overdue. He is waiting for a catalyst. They have very little debt. It could take some tax loss selling before the end of the year, and he has it on his Buy list. Does digitization and a lot in the Tech Arena.
This does digitalization. They are into e-books, work with the insurance industry and with the healthcare sector. This has virtually no debt. In the last few years they have lost a fair bit of money, and right now are operating at about breakeven. Wishes management were a bit more proactive. Just did a takeover of another company, but there is little information in the public sphere. The stock price tends not to be a slow grower, but tends to jump. He has a target price of over $7. His hope is that it will have one of the spikes that it has every few years, at which time he would jump out very, very quickly.
(A Top Pick Dec 23/14. Down 1.78%.) He likes this a lot. Revenues were $87 million a few years ago, and are now down to about $60 million. This deals with digitization, e-books types of things. Revenues last quarter went up 8%. They are going to make some money because they just did a deal with John Hancock Insurance. They are hoping to expand with them and with other insurers. They’ll also get some business because of the Basil Accord, because a lot of companies are going to need a lot more documentation. He can see the stock going up over $6.
Bought this company a number of years ago and paid $2.56. Sold it in 14 months at $6 plus. They do digitalization and are into e-books and work with insurance companies. Bought it again at $2.46, and feels that can get back to over $7 again. It has a tendency to run every few years, and really go into spikes. Charts show 3 spikes over the last 10 years, so he imagines this could possibly happen again. It is clean, clean in terms of debt. Revenues have been coming down. Lost $10 million last year, but about half of that was write offs. Right now they are running at about breakeven. Thinks it is a good turnaround play. With almost no debt, he doesn’t see any real danger signals.
Innodata Isogen Inc. is a American stock, trading under the symbol INOD-Q on the NASDAQ (INOD). It is usually referred to as NASDAQ:INOD or INOD-Q
In the last year, 1 stock analyst published opinions about INOD-Q. 0 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Innodata Isogen Inc..
Innodata Isogen Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for Innodata Isogen Inc..
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
1 stock analyst on Stockchase covered Innodata Isogen Inc. In the last year. It is a trending stock that is worth watching.
On 2025-04-01, Innodata Isogen Inc. (INOD-Q) stock closed at a price of $36.54.
It's become very expensive. Take some profits.